38.63 USD
+0.66 (+1.74%)
38.63 USD
0 (0%)
CSTL gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 100 industry peers in the Health Care Providers & Services industry. While CSTL has a great health rating, there are worries on its profitability. While showing a medium growth rate, CSTL is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year CSTL was profitable.
CSTL had a positive operating cash flow in the past year.
CSTL had negative earnings in 4 of the past 5 years.
In multiple years CSTL reported negative operating cash flow during the last 5 years.
1.2 Ratios
CSTL has a Return On Assets (-2.17%) which is in line with its industry peers.
Looking at the Return On Equity, with a value of -2.62%, CSTL is in line with its industry, outperforming 50.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.17% | ||
| ROE | -2.62% | ||
| ROIC | N/A |
ROA(3y)-8.08%
ROA(5y)-6.67%
ROE(3y)-9.16%
ROE(5y)-7.51%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CSTL's Profit Margin has been stable in the last couple of years.
In the last couple of years the Operating Margin of CSTL has declined.
CSTL has a Gross Margin of 79.94%. This is amongst the best in the industry. CSTL outperforms 95.00% of its industry peers.
In the last couple of years the Gross Margin of CSTL has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for CSTL so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 79.94% |
OM growth 3YN/A
OM growth 5Y-28.6%
PM growth 3YN/A
PM growth 5Y-1.01%
GM growth 3Y-0.54%
GM growth 5Y-0.96%
2. Health
2.1 Basic Checks
CSTL does not have a ROIC to compare to the WACC, probably because it is not profitable.
CSTL has more shares outstanding than it did 1 year ago.
CSTL has more shares outstanding than it did 5 years ago.
The debt/assets ratio for CSTL is higher compared to a year ago.
2.2 Solvency
CSTL has an Altman-Z score of 7.56. This indicates that CSTL is financially healthy and has little risk of bankruptcy at the moment.
CSTL has a better Altman-Z score (7.56) than 94.00% of its industry peers.
The Debt to FCF ratio of CSTL is 0.41, which is an excellent value as it means it would take CSTL, only 0.41 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 0.41, CSTL belongs to the top of the industry, outperforming 92.00% of the companies in the same industry.
A Debt/Equity ratio of 0.02 indicates that CSTL is not too dependend on debt financing.
CSTL's Debt to Equity ratio of 0.02 is amongst the best of the industry. CSTL outperforms 82.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.41 | ||
| Altman-Z | 7.56 |
ROIC/WACCN/A
WACC8.82%
2.3 Liquidity
CSTL has a Current Ratio of 6.47. This indicates that CSTL is financially healthy and has no problem in meeting its short term obligations.
CSTL has a better Current ratio (6.47) than 96.00% of its industry peers.
CSTL has a Quick Ratio of 6.31. This indicates that CSTL is financially healthy and has no problem in meeting its short term obligations.
CSTL has a better Quick ratio (6.31) than 96.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.47 | ||
| Quick Ratio | 6.31 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 30.00% over the past year.
Measured over the past years, CSTL shows a very strong growth in Earnings Per Share. The EPS has been growing by 29.69% on average per year.
CSTL shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 10.15%.
The Revenue has been growing by 44.95% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)30%
EPS 3YN/A
EPS 5Y29.69%
EPS Q2Q%-125%
Revenue 1Y (TTM)10.15%
Revenue growth 3Y52.25%
Revenue growth 5Y44.95%
Sales Q2Q%-3.19%
3.2 Future
Based on estimates for the next years, CSTL will show a very negative growth in Earnings Per Share. The EPS will decrease by -17.28% on average per year.
CSTL is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.51% yearly.
EPS Next Y-281.8%
EPS Next 2Y-107.44%
EPS Next 3Y-50.14%
EPS Next 5Y-17.28%
Revenue Next Year1.09%
Revenue Next 2Y0.09%
Revenue Next 3Y4.42%
Revenue Next 5Y6.51%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 148.58, which means the current valuation is very expensive for CSTL.
Compared to the rest of the industry, the Price/Earnings ratio of CSTL is on the same level as its industry peers.
CSTL's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 26.56.
CSTL is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 148.58 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, CSTL is valued a bit more expensive than the industry average as 63.00% of the companies are valued more cheaply.
CSTL's Price/Free Cash Flow ratio is in line with the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 44.43 | ||
| EV/EBITDA | 82.83 |
4.3 Compensation for Growth
A cheap valuation may be justified as CSTL's earnings are expected to decrease with -50.14% in the coming years.
PEG (NY)N/A
PEG (5Y)5
EPS Next 2Y-107.44%
EPS Next 3Y-50.14%
5. Dividend
5.1 Amount
No dividends for CSTL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
38.63
+0.66 (+1.74%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners90.57%
Inst Owner Change-3.52%
Ins Owners2.48%
Ins Owner Change-1.65%
Market Cap1.13B
Revenue(TTM)343.53M
Net Income(TTM)-12.24M
Analysts88.57
Price Target38.51 (-0.31%)
Short Float %5.89%
Short Ratio4.17
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)112.17%
Min EPS beat(2)96.25%
Max EPS beat(2)128.1%
EPS beat(4)3
Avg EPS beat(4)151.85%
Min EPS beat(4)-175.74%
Max EPS beat(4)558.79%
EPS beat(8)7
Avg EPS beat(8)149.84%
EPS beat(12)10
Avg EPS beat(12)106.51%
EPS beat(16)13
Avg EPS beat(16)87.37%
Revenue beat(2)2
Avg Revenue beat(2)16.33%
Min Revenue beat(2)14.33%
Max Revenue beat(2)18.34%
Revenue beat(4)4
Avg Revenue beat(4)10.84%
Min Revenue beat(4)3.31%
Max Revenue beat(4)18.34%
Revenue beat(8)8
Avg Revenue beat(8)11.87%
Revenue beat(12)12
Avg Revenue beat(12)11.82%
Revenue beat(16)16
Avg Revenue beat(16)10.9%
PT rev (1m)5.96%
PT rev (3m)5.96%
EPS NQ rev (1m)2.83%
EPS NQ rev (3m)31.25%
EPS NY rev (1m)37.96%
EPS NY rev (3m)38.5%
Revenue NQ rev (1m)0.77%
Revenue NQ rev (3m)4.75%
Revenue NY rev (1m)4.24%
Revenue NY rev (3m)4.24%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 148.58 | ||
| Fwd PE | N/A | ||
| P/S | 3.28 | ||
| P/FCF | 44.43 | ||
| P/OCF | 18.25 | ||
| P/B | 2.41 | ||
| P/tB | 3.09 | ||
| EV/EBITDA | 82.83 |
EPS(TTM)0.26
EY0.67%
EPS(NY)-1.45
Fwd EYN/A
FCF(TTM)0.87
FCFY2.25%
OCF(TTM)2.12
OCFY5.48%
SpS11.77
BVpS16
TBVpS12.51
PEG (NY)N/A
PEG (5Y)5
Graham Number9.67
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.17% | ||
| ROE | -2.62% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 79.94% | ||
| FCFM | 7.39% |
ROA(3y)-8.08%
ROA(5y)-6.67%
ROE(3y)-9.16%
ROE(5y)-7.51%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5Y-28.6%
PM growth 3YN/A
PM growth 5Y-1.01%
GM growth 3Y-0.54%
GM growth 5Y-0.96%
F-Score4
Asset Turnover0.61
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.41 | ||
| Debt/EBITDA | 1.33 | ||
| Cap/Depr | 85.13% | ||
| Cap/Sales | 10.6% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 789.13% | ||
| Profit Quality | N/A | ||
| Current Ratio | 6.47 | ||
| Quick Ratio | 6.31 | ||
| Altman-Z | 7.56 |
F-Score4
WACC8.82%
ROIC/WACCN/A
Cap/Depr(3y)113.65%
Cap/Depr(5y)290.73%
Cap/Sales(3y)6.28%
Cap/Sales(5y)6.02%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)30%
EPS 3YN/A
EPS 5Y29.69%
EPS Q2Q%-125%
EPS Next Y-281.8%
EPS Next 2Y-107.44%
EPS Next 3Y-50.14%
EPS Next 5Y-17.28%
Revenue 1Y (TTM)10.15%
Revenue growth 3Y52.25%
Revenue growth 5Y44.95%
Sales Q2Q%-3.19%
Revenue Next Year1.09%
Revenue Next 2Y0.09%
Revenue Next 3Y4.42%
Revenue Next 5Y6.51%
EBIT growth 1Y-3265.41%
EBIT growth 3YN/A
EBIT growth 5Y3.5%
EBIT Next Year571.08%
EBIT Next 3Y-53.98%
EBIT Next 5Y-26.67%
FCF growth 1Y160.68%
FCF growth 3YN/A
FCF growth 5Y43.14%
OCF growth 1Y304.51%
OCF growth 3YN/A
OCF growth 5Y56%
CASTLE BIOSCIENCES INC / CSTL FAQ
What is the fundamental rating for CSTL stock?
ChartMill assigns a fundamental rating of 5 / 10 to CSTL.
What is the valuation status for CSTL stock?
ChartMill assigns a valuation rating of 1 / 10 to CASTLE BIOSCIENCES INC (CSTL). This can be considered as Overvalued.
Can you provide the profitability details for CASTLE BIOSCIENCES INC?
CASTLE BIOSCIENCES INC (CSTL) has a profitability rating of 3 / 10.
What is the valuation of CASTLE BIOSCIENCES INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for CASTLE BIOSCIENCES INC (CSTL) is 148.58 and the Price/Book (PB) ratio is 2.41.
How financially healthy is CASTLE BIOSCIENCES INC?
The financial health rating of CASTLE BIOSCIENCES INC (CSTL) is 8 / 10.